Skip to main content

Digilab Biovision to Sell GenWay's Seppro IgY Proteomics Technology

NEW YORK (GenomeWeb News) — Digilab BioVision today said it will offer GenWay Biotech’s Seppro IgY proteomics technology from its Hannover, Germany, facility.
 
Digilab said Seppro’s IgY technology selectively partitions the 12 most abundant proteins from human serum or plasma.
 
Digilab said its Peptidomics products and services increase the sensitivity and selectivity needed for drug-development proteomics.
 
Financial terms of the agreement were not released.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.